menu
    • menu

    Company profile for Replimune

    NEW Drugs in Dev: 6
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Replimune has assembled a world-class team who together pioneered the development of the first FDA-approved oncolytic immunotherapy. Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic ...
    Replimune has assembled a world-class team who together pioneered the development of the first FDA-approved oncolytic immunotherapy. Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic anti-tumor immune response.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ReplimuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    18 Commerce Way Woburn MA 01801
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://replimune.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/replimune-inc
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/replimune?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Replimune Updates On Q3 2026 Finances & Corporate Progress
    Replimune Updates On Q3 2026 Finances & Corporate Progress

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3230977/0/en/Replimune-Reports-Fiscal-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Replimune To Present At J.P. Morgan Healthcare Conference
    Replimune To Present At J.P. Morgan Healthcare Conference

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207643/0/en/Replimune-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Replimune Unveils RP1 Data at SITC 2025 Meeting
    Replimune Unveils RP1 Data at SITC 2025 Meeting

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183988/0/en/Replimune-Presents-Late-Breaking-Abstract-and-Additional-Posters-on-RP1-at-40th-Annual-Meeting-of-the-Society-for-the-Immunotherapy-of-Cancer-SITC-2025.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Replimune’s RP1 BLA for Advanced Melanoma Accepted by FDA
    Replimune’s RP1 BLA for Advanced Melanoma Accepted by FDA

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169221/0/en/Replimune-Announces-FDA-Acceptance-of-BLA-Resubmission-of-RP1-for-the-Treatment-of-Advanced-Melanoma.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share
    Replimune's Stock Spikes 100% On FDA Acceptance Of Resubmission
    Replimune's Stock Spikes 100% On FDA Acceptance Of Resubmission

    20 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/fda-accepts-replimunes-resubmission-setting-decision-date-april-and-spiking-biotechs-stock

    FIERCE BIOTECH
    20 Oct 2025
    Share Share
    Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab
    Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab

    19 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/19/3169018/0/en/Replimune-Highlights-Acral-Melanoma-Data-for-RP1-plus-Nivolumab-at-the-ESMO-Congress-2025.html

    GLOBENEWSWIRE
    19 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search